Document is current
Any future updates will be listed below
-
Authors
Liu, Weihai
Wang, Yun
Bozi, Luiz H. M.
Fischer, Patrick D. https://orcid.org/0000-0003-4160-5295
Jedrychowski, Mark P.
Xiao, Haopeng https://orcid.org/0000-0002-4166-647X
Wu, Tao
Darabedian, Narek
He, Xiadi
Mills, Evanna L. https://orcid.org/0000-0003-0447-8995
Burger, Nils https://orcid.org/0000-0003-3227-8894
Shin, Sanghee
Reddy, Anita
Sprenger, Hans-Georg
Tran, Nhien
Winther, Sally
Hinshaw, Stephen M.
Shen, Jingnan
Seo, Hyuk-Soo https://orcid.org/0000-0003-0646-2102
Song, Kijun https://orcid.org/0000-0002-6037-9345
Xu, Andrew Z.
Sebastian, Luke https://orcid.org/0000-0002-6863-9420
Zhao, Jean J. https://orcid.org/0000-0002-4561-5688
Dhe-Paganon, Sirano https://orcid.org/0000-0003-0824-5929
Che, Jianwei
Gygi, Steven P. https://orcid.org/0000-0001-7626-0034
Arthanari, Haribabu
Chouchani, Edward T. https://orcid.org/0000-0002-9776-8790
- License Information
-
More Information
Article History
Received: 21 November 2021
Accepted: 10 March 2023
First Online: 15 March 2023
Competing interests
: J.Z. is co-founder and board director of Crimson Biopharm Inc. and Geode Therapeutics Inc. E.T.C. is co-founder of Matchpoint Therapeutics and Aevum Therapeutics. J.C. is a co-founder for Matchpoint Therapeutics. J.C. is a scientific co-founder M3 Bioinformatics & Technology Inc., and consultant and equity holder for Soltego and Allorion. All other authors declare no competing interests.
